Download PDF
Thromb Haemost 1984; 51(03): 307-312
DOI: 10.1055/s-0038-1661089
Original Article
Schattauer GmbH Stuttgart

Platelet Survival in Streptozotocin-Induced Diabetic Rats

P D Winocour
The Veterans Administration Medical Center and Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
,
M Laimins
The Veterans Administration Medical Center and Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
,
J A Colwell
The Veterans Administration Medical Center and Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 22 July 1983

Accepted 24 January 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Platelet survival in diabetes mellitus may be decreased or normal, and it is not clear whether altered platelet survival is due to a platelet or to a non-platelet defect. Therefore, platelet survival studies were performed at intervals up to 28 days in streptozotocin-induced diabetic and normal rats, using washed platelets from diabetic or normal animals.

When compared to platelets from control rats, there was a significant decrease in platelet survival when platelets from 7 and 14 day diabetic rats were injected into normal controls or into diabetic rats.

After 28 days of diabetes, platelet survival in diabetic rats was significantly lengthened, whether the platelets came from control or diabetic rats.

Conclusions. (1) Shortened platelet survival in the diabetic rat is caused initially by a platelet defect. Later, non-platelet factors become dominant. (2) These findings may help explain reported discrepancies in results of platelet survival in diabetes mellitus.

Keywords

Platelet survival - Diabetes mellitus - Rats
 

  • References

  • 1 Colwell JA, Lopes-Virella M, Halushka PV. Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care 1981; 4: 121-133
    CrossrefPubMedSearch in Google Scholar
  • 2 Bern MM. Platelet function in diabetes mellitus. Diabetes 1978; 27: 342-350
    CrossrefPubMedSearch in Google Scholar
  • 3 Abrahamsen AF. Platelet survival studies in man: With special reference to thrombosis and atherosclerosis. Scand J Haematol 1968; Suppl 3: 7-53
    PubMedSearch in Google Scholar
  • 4 Jones RL, Paradise C, Peterson CM. Platelet survival in patients with diabetes mellitus. Diabetes 1981; 30: 486-489
    CrossrefPubMedSearch in Google Scholar
  • 5 Dassin E, Najean Y, Poirier O, Passa Ph, Bensoussan D. In vivo platelet kinetics in 31 diabetic patients. Correlation with the degree of vascular impairment Thromb Haemostas 1978; 40: 83-88
    PubMedSearch in Google Scholar
  • 6 Ferguson JC, Mackay N, Philip JA, Summer DJ. Determination of platelet and fibrinogen half-life with [75-Se]-selenomethionine: Studies in normal and in diabetic subjects. Clin Sci Mol Med 1975; 49: 115-120
    PubMedSearch in Google Scholar
  • 7 Paton RC. Platelet survival in diabetes mellitus using an aspirinlabelling technique. Thromb Res 1979; 15: 793-802
    CrossrefPubMedSearch in Google Scholar
  • 8 Kazmier FJ, Fuster V, Chesebro JH, O’Fallon WM, Palumbo PJ. Platelet survival half-life (PS) in atherosclerosis and diabetes mellitus. Circulation 1979; 59 and 60 Suppl (Suppl. 02) 270
    PubMedSearch in Google Scholar
  • 9 Johnson M, Harrison HE, Hawker L. Platelet abnormalities in experimental diabetes. Thromb Haemostas 1979; 42: 333 (Abstr.)
    PubMedSearch in Google Scholar
  • 10 Colwell JA, Sagel J, Crook L, Chambers A, Laimins m. Correlation of platelet aggregation, plasma factor activity and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism 1977; 26: 279-285
    CrossrefPubMedSearch in Google Scholar
  • 11 Garg SK, Lackner H, Karpatkin S. The increased percentage of megathrombocytes in various clinical disorders. Ann Intern Med 1972; 77: 361-369
    CrossrefPubMedSearch in Google Scholar
  • 12 Karpatkin S. Biochemical and clinical aspects of megathrombocytes. Ann NY Acad Sci 1972; 201: 262-279
    CrossrefPubMedSearch in Google Scholar
  • 13 Karpatkin S. Heterogeneity of human platelets. II Functional evidence suggestive of young and old platelets. J Clin Invest 1969; 48: 1083-1087
    CrossrefPubMedSearch in Google Scholar
  • 14 Hirsh J, Glynn MF, Mustard JF. The effect of platelet age on platelet adherence to collagen. J Clin Invest 1968; 47: 466-473
    CrossrefPubMedSearch in Google Scholar
  • 15 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-855
    CrossrefPubMedSearch in Google Scholar
  • 16 Ardlie NG, Packham MA, Mustard JF. Adenosine diphosphate- induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol 1970; 19: 7-17
    CrossrefPubMedSearch in Google Scholar
  • 17 Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3: 365-377
    CrossrefPubMedSearch in Google Scholar
  • 18 Murphy EA, Bolling DR. Platelet survival. In: Platelet Function Testing. Day JH, Holmsen H, Zucker MB. (eds) DHEW Publication; No.(NIH) 78: 1087 1978. pp 561-567
    Search in Google Scholar
  • 19 Murphy EA, Francis ME, Bolling DR. Estimation of blood platelet survival. V. A method for the analysis of population data. J Chron Dis 1973; 26: 797-815
    CrossrefPubMedSearch in Google Scholar
  • 20 Scheffel U, McIntyre PA, Evatt B, Dvomicky Jr JA, Natarajan TK, Bolling DR, Murphy EA. Evulation of Indium-111 as a new high photon yield gamma emitting “physiological” platelet label. Johns Hopkins Med J 1977; 140: 285-293
    PubMedSearch in Google Scholar
  • 21 Kadish AH, Little RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116-131
    PubMedSearch in Google Scholar
  • 22 Turpie AG G, Genton E, Han P, de Boer AC, Gent M. Evaluation of gamma function calculation of platelet survival time (PSST). Circulation 1980; 62 Suppl (Suppl. 03) 277
    CrossrefPubMedSearch in Google Scholar
  • 23 Heath H, Brigden WD, Canever JR, Pollock J, Hunter PR, Kelsey J, Bloom A. Platelet adhesiveness and aggregation in relation to diabetic retinopathy. Diabetologia 1971; 7: 308-315
    CrossrefPubMedSearch in Google Scholar
  • 24 Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 1972; 80: 236-246
    PubMedSearch in Google Scholar
  • 25 Passa Ph, Bensoussan D, Levy-Toledano S, Caen J, Canivet J. Etude de l’agrégation plaquettaire au cours de la rétinopathie diabétique. Atherosclerosis 1974; 19: 277-287
    CrossrefPubMedSearch in Google Scholar
  • 26 Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med 1975; 82: 733-738
    CrossrefPubMedSearch in Google Scholar
  • 27 Halushka PV, Lurie D, Colwell JA. Increased synthesis of prostaglandin E-like material by platelets from patients with diabetes mellitus. N Engl J Med 1977; 297: 1306-1310
    CrossrefPubMedSearch in Google Scholar
  • 28 Mustard JF. Function of blood platelets and their role in thrombosis. Trans Am Clin Climatol Assoc 1976; 87: 104-127
    PubMedSearch in Google Scholar
  • 29 Rutherford RB, Ross R. Platelet factors stimulate fibroblasts and smooth muscle cells quiescent in plasma serum to proliferate. J Cell Biol 1976; 69: 196-203
    CrossrefPubMedSearch in Google Scholar
  • 30 Winocour PD, Laimins M, Lopes-Virella M, Colwell JA. The time course of changes in vitro platelet function and plasma von Willebrand factor (VIIIR: WF) activity in the diabetic rat. J Lab Clin Med 1983; 102: 795-804
    PubMedSearch in Google Scholar
  • 31 Van Zile J, Kilpatrick M, Laimins M, Sagel J, Colwell JA, Virella G. Platelet aggregation and release of ATP after incubation with soluble immune complexes purified from the serum of diabetic patients. Diabetes 1981; 30: 575-579
    CrossrefPubMedSearch in Google Scholar
  • 32 Eldor A, Merin S, Bar-On H. The effect of streptozotocin diabetes on platelet function in rats. Thromb Res 1978; 13: 703-714
    CrossrefPubMedSearch in Google Scholar
  • 33 Winocour PD, Kinlough-Rathbone RL, Richardson M, Mustard JF. Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon-aminocaproic acid. J Clin Invest 1983; 71: 159-164
    CrossrefPubMedSearch in Google Scholar
  • 34 Aimer L-O, Pandolfi M. Fibrinolysis and diabetic retinopathy. Diabetes 1976; 25 Suppl (Suppl. 02) 807-810
    PubMedSearch in Google Scholar
  • 35 Feamley GR, Chakrabarti R, Avis PR D. Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. Br Med J 1963; 1: 921-923
    CrossrefPubMedSearch in Google Scholar
  • 36 Nenci GG, Berrettini M, Agnelli G, Parise P, Buoncristiani U, Ballatori E. Effect of peritoneal dialysis hemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine. Nephron 1979; 23: 287-292
    CrossrefPubMedSearch in Google Scholar
  • 37 Janka HU, Demmel P. Influence of metabolic control on platelet functions in diabetes mellitus. Horm Metab Res Suppl 1981; 2: 29-33
    PubMedSearch in Google Scholar
  • 38 Schedl HP. Effects of experimental diabetes in the rat on calium transport and vitamin D metabolism. In: Vitamin D Basic Research and Its Clinical Application. Proceeding of the Fourth Workshop on Vitamin D, Berlin, West Germany. Norman AW, Schaefer K, Herrath DV, Grigoleit HG, Cobum JW, DeLuca HF, Mawer EB, Suda T. (eds) Walter de Gruyter; Berlin, NY: 1979. pp 967-974
    Search in Google Scholar
  • 39 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
    CrossrefPubMedSearch in Google Scholar